Effect of Biologics in Subgroups of Axial Spondyloarthritis Based on Magnetic Resonance Imaging and C-Reactive Protein: A Systematic Review and Meta-Analysis.

OBJECTIVE To determine if the efficacy of biologics differ based on magnetic resonance imaging (MRI) and C-reactive protein (CRP) findings. METHODS We compared four subgroups (MRI+/CRP+, MRI+/CRP-, MRI-/CRP+, MRI-/CRP-) from randomized controlled trials (RCTs). A comprehensive database search was performed to include axial spondylarthritis (axSpA; both radiographic axSpA [r-axSpA] and nonradiographic axSpA [nr-axSpA]) RCTs with treatment efficacy reported by different MRI and CRP subgroups. Study-specific disease activity scores (at 12-16 weeks) were pooled using a random-effects model and compared between the four subgroups. RESULTS Five trials (all nr-axSpA) were included: three with tumor necrosis factor inhibitors (TNFi, N = 729) and two with interleukin-17 inhibitors (IL-17i, N = 794). TNFi and IL-17i showed efficacy based on the Assessment of Spondyloarthritis International Society 40 (ASAS40) and Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50) in all MRI and CRP subgroups, except the CRP-/MRI- subgroup, which had a single study with only 39 patients. There was no statistically significant difference between the four subgroups in terms of patients achieving ASAS40 (P = 0.60, I2 = 0%) or BASDAI50 (P = 0.27, I2 = 23.9%). The number needed to treat was three for the CRP+/MRI+ and CRP+/MRI- subgroups and six for the CRP-/MRI+ and CRP-/MRI- subgroups. All trials had a low risk of bias. Between-study heterogeneity was low to moderate. Sensitivity analyses comparing TNFi or IL-17i versus placebo similarly showed no difference between subgroups in terms of ASAS40 (TNFi, P = 0.57; IL-17i, P = 0.28) and BASDAI50 (TNFi, P = 0.37; IL-17i, P = 0.18). CONCLUSION In this systematic review, there was no statistically significant difference between the four subgroups in terms of efficacy based on ASAS40 or BASDAI50.

[1]  R. Landewé,et al.  ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update , 2022, Annals of the Rheumatic Diseases.

[2]  W. Maksymowych,et al.  Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol , 2021, Arthritis Research & Therapy.

[3]  A. Deodhar,et al.  Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT , 2021, Arthritis Research & Therapy.

[4]  S. Rodrigues-Manica,et al.  Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis. , 2020, Rheumatology.

[5]  R. Landewé,et al.  Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study , 2019, RMD Open.

[6]  H. Jones,et al.  The role of C-reactive protein as a predictor of treatment response in patients with ankylosing spondylitis. , 2019, Seminars in arthritis and rheumatism.

[7]  M. Brown,et al.  Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study , 2017, Annals of the Rheumatic Diseases.

[8]  H. Murad.  Clinical Practice Guidelines , 2017, Mayo Clinic proceedings.

[9]  M. Dougados,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis , 2015, Arthritis & rheumatology.

[10]  J. MacKay,et al.  Correlation between clinical and MRI disease activity scores in axial spondyloarthritis , 2015, Clinical Rheumatology.

[11]  J. Gómez-Reino,et al.  Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis , 2015, RMD Open.

[12]  M. Dougados,et al.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study , 2013, Annals of the rheumatic diseases.

[13]  R. Landewé,et al.  MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor , 2012, Annals of the rheumatic diseases.

[14]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[15]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.

[16]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[17]  D. M. van der Heijde,et al.  Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group , 2009, Annals of the rheumatic diseases.

[18]  Paul Wordsworth,et al.  Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis , 2009, The Journal of Rheumatology.

[19]  M. Dougados,et al.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal , 2009, Annals of the rheumatic diseases.

[20]  E. Märker-Hermann,et al.  The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. , 2009, Arthritis and rheumatism.

[21]  J. Braun,et al.  MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis , 2007, Annals of the rheumatic diseases.

[22]  M. Stone,et al.  Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. , 2005, Arthritis and rheumatism.

[23]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[24]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.